Methylprednisolone inhibits granulocytopenia induced by infusion of complement-activated serum but not of complement-activated plasma in rabbits.
The effect of methylprednisolone was examined on complement-induced granulocytopenia in vivo following infusion of zymosan-activated autologous plasma or serum into rabbits. Methylprednisolone only inhibited granulocytopenia and thrombocytopenia when zymosan-activated serum or fibrinogen-depleted plasma were infused. It was ineffective at preventing granulocytopenia in animals infused with zymosan-activated plasma. Only zymosan-activated plasma contained fibrin monomers which could directly cause granulocytopenia independently of the generation of C5a. Hence, during complement activation in whole blood in vivo, little or no effect of methylprednisolone should be expected in preventing granulocytopenia.
Jansen
N J
NJ
Department of Cardiopulmonary Surgery, University Hospital, Groningen, The Netherlands.
van Oeveren
W
W
Wildevuur
C R
CR
Kazatchkine
M D
MD
D000380:Agranulocytosis / Q000503:physiopathology*; D000818:Animals; D003167:Complement Activation / Q000502:physiology*; D007958:Leukocyte Count / Q000187:drug effects; D008775:Methylprednisolone / Q000494:pharmacology*; D010949:Plasma / Q000502:physiology*; D011817:Rabbits; D013921:Thrombocytopenia / Q000503:physiopathology*
D008775:Methylprednisolone